Newport Beach, CA – According to filings with the U.S. Securities and Exchange Commission, TriFlo Cardiovascular is raising $12,075,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Luca Pesce played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About TriFlo Cardiovascular
TriFlo is focused on taking to clinical trials a unique minimally invasive transcatheter solution to treat tricuspid valve regurgitation. TriFlo operator of a biotechnology firm focusing on an invasive transcatheter solution to treat tricuspid valve regurgitation.

To learn more about TriFlo Cardiovascular, visit http://triflocv.com/

Contact:
Luca Pesce, President and Chief Executive Officer
626-922-4745

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved